{
  "abstract": "Introduction Pulsed Field Ablation (PFA) is a novel, non-thermal method for cardiac ablation that induce a safe irreversible electroporation of cardiac myocyte without damaging adjacent structures ( figure 1). PFA may have effectiveness comparable to that of traditional catheter ablation but without the thermally induced complications. Nonetheless, Data about PFA application, safety and implication are really scarce in Jordan and the Middle east region.Methods We conducted a retrospective chart review of all patients undergoing PFA ablation for AF at a single tertiary center between January and September of 2025. Patients’ demographic characteristics, comorbidities, medication history, laboratory measures, and imaging studies were retrieved and described. Rate of recurrence within 3 months was considered the primary endpoint. Rates of Complications including access site complications, bleeding requiring transfusion, cardiac tamponade, recurrent laryngeal nerve injury and pulmonary vein stenosis were considered secondary safety endpoints. Data was cleaned and analyzed using SPSS ver. 23.Results A total of 52 patients, characterized by a mean age of 58.8 ± 16.8 years, were included in the study with male-to-female ratio of 1.08:1 ( table 1). Patients’ systolic and diastolic blood pressures were 139.2 ± 19.1 mmHg and 78.0 ± 9.4 mmHg, respectively. The cohort’s left atrial diameter was 3.8 ± 0.6 cm, while their left atrial volume was 106.6 ± 33.0 ml. Among participants, hypertension was the most commonly reported comorbidity (55.8%). Beta blockers and oral anticoagulants were the most commonly utilized medications (86.5% and 86.5%, respectively). Across a follow up period of 3 months, only 4 out of 52 patients (7.7%) had experienced AF recurrence. None of the study participants experienced any of the study secondary end-points (table 2).Conclusion The observed rate of early AF recurrence for PFA in our study is significantly more favorable compared to the reported rates for its traditional catheter ablation counterpart (i.e., 24 – 50%). The significance of these differences across a larger sample size and a longer temporal frame are required for confirmation. Nonetheless, these are considered the first and earliest reports of PFA efficacy and safety in the Middle East region.Abstract 520 Table 1baseline demographics and clinical characteristics of the study population (N = 52)CharacteristicValueDemographics Gender (Male), n (%)Age (Years), mean ± SDFamily History a, n (%)27 (51.9%)58.8 ± 16.811 (21.2%)Social History Smoking b, n (%)Alcohol c, n (%)Caffeine d, n (%)20 (42.6%)7 (14.9%)26 (55.3%)Medical History Hypertension, n (%)Diabetes Mellitus, n (%)Heart Failure, n (%)Cardiac Surgical History e, n (%)Non-cardiac Surgical HistoryCHA2DS2-VASc score, mean ± SD29 (55.8%)15 (28.8%)8 (15.4%)22 (42.3%)29 (55.8%)1.9 ± 1.8Clinical and Echocardiographic Parameters Systolic Blood Pressure (mmHg), mean ± SDDiastolic Blood Pressure (mmHg), mean ± SDLeft Atrial Diameter (mm), mean ± SDLeft Atrial Volume (mL), mean ± SD139.2 ± 19.178 ± 9.43.8 ± 0.6106.6 ± 33Notes: aDefined as first-degree relative with atrial tachyarrhythmia. b Defined as currently smokes or ever smoked within the last 6 months. c Defined as consuming at least 1 units of alcohol daily for women and 2 units daily for men. d Defined as the consumption of more than 3 caffeinated beverages per day. e Defined as having any previous history of cardiac intervention excluding atrial fibrillation ablation. Abbreviations: SD: Standard DeviationAbstract 520 Table 2Procedural and recurrence metricsProcedural CharacteristicsValueProcedure Duration (Minutes), mean ± SD77 ± 12.3Fluoroscopy Time (Minutes), mean ± SD16 ± 1.73D Mapping Usage, n (%)12 (23.1)Recurrence Parameters Recurrence Rate, n (%)4 (7.7%)Follow-up Period (Days), mean ± SD132.5 ± 41.3Procedure-to-recurrence (Days), median (range)121 (2 – 136)Abstract 520 Figure 1Fluoroscopic visualization of the PFA ablation catheter during the procedure",
  "authors": [
    {
      "affiliations": [
        "Abdali Medical Center, Amman, Jordan",
        "Ministry of Health, Amman, Jordan"
      ],
      "name": "Abdalrahman Al-slaimieh"
    },
    {
      "affiliations": [
        "Abdali Medical Center, Amman, Jordan"
      ],
      "name": "Nour Haj Ali"
    },
    {
      "affiliations": [
        "Abdali Medical Center, Amman, Jordan"
      ],
      "name": "Khaled Abukhalaf"
    },
    {
      "affiliations": [
        "Abdali Medical Center, Amman, Jordan"
      ],
      "name": "Jude Awad"
    },
    {
      "affiliations": [
        "Boston Children’s Hospital, Boston, United States"
      ],
      "name": "Abdallah Al-Ani"
    },
    {
      "affiliations": [
        "Istishari Hospital, Amman, Jordan"
      ],
      "name": "Ayman Hammoudeh"
    },
    {
      "affiliations": [
        "Abdali Medical Center, Amman, Jordan"
      ],
      "name": "Mohammad Hajjiri"
    }
  ],
  "title": "520 Efficacy and safety of pulsed field ablation for the treatment of atrial fibrillation: early report from the MENA region",
  "uid": "d13982ff-b021-5956-8617-a03bdd998376"
}